AGÕæÈ˹ٷ½

STOCK TITAN

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Klotho Neurosciences (NASDAQ:KLTO) has received FDA Orphan Drug Designation for KLTO-202, its novel secreted-Klotho promoter gene therapy for treating Amyotrophic Lateral Sclerosis (ALS). This designation provides significant benefits including tax credits for clinical trials, GDUFA User Fee waivers, and 7 years of market exclusivity.

KLTO-202 targets motor neuron diseases using a muscle-specific promoter called "desmin" to express the s-KL gene and protein, specifically delivering therapy to the neuromuscular junction. The company has completed proof of concept studies in two animal models and is initiating manufacturing while planning regulatory meetings with the FDA and EMA.

Klotho Neurosciences (NASDAQ:KLTO) ha ottenuto la Designazione di Farmaco Orfano dalla FDA per KLTO-202, la sua nuova terapia genica che promuove il gene secreted-Klotho per il trattamento della Sclerosi Laterale Amiotrofica (SLA). Questa designazione offre importanti vantaggi, tra cui crediti d'imposta per gli studi clinici, esenzioni dalle tariffe GDUFA e 7 anni di esclusività sul mercato.

KLTO-202 agisce contro le malattie dei motoneuroni utilizzando un promotore specifico per i muscoli chiamato "desmina" per esprimere il gene e la proteina s-KL, fornendo la terapia in modo mirato alla giunzione neuromuscolare. L'azienda ha completato studi di prova del concetto su due modelli animali e sta avviando la produzione, pianificando inoltre incontri regolatori con FDA ed EMA.

Klotho Neurosciences (NASDAQ:KLTO) ha recibido la Designación de Medicamento Huérfano por la FDA para KLTO-202, su novedosa terapia génica promotora del gen secreted-Klotho para el tratamiento de la Esclerosis Lateral Amiotrófica (ELA). Esta designación ofrece beneficios importantes, incluyendo créditos fiscales para ensayos clínicos, exenciones de tarifas GDUFA y 7 años de exclusividad en el mercado.

KLTO-202 se dirige a enfermedades de las neuronas motoras usando un promotor específico para músculos llamado "desmina" para expresar el gen y la proteína s-KL, entregando la terapia específicamente en la unión neuromuscular. La compañía ha completado estudios de prueba de concepto en dos modelos animales y está iniciando la fabricación mientras planea reuniones regulatorias con la FDA y la EMA.

Klotho Neurosciences (NASDAQ:KLTO)ëŠ� 근위축성 측삭 경화ì¦�(ALS) 치료ë¥� 위한 새로ìš� 분비í˜� Klotho 프로모터 유전ìž� ì¹˜ë£Œì œì¸ KLTO-202ì—� 대í•� FDA í¬ê·€ì˜ì•½í’� ì§€ì �(Orphan Drug Designation)ì� 받았습니ë‹�. ì� ì§€ì •ì€ ìž„ìƒì‹œí—˜ 세액 공제, GDUFA 사용ìž� 수수ë£� ë©´ì œ, 7ë…„ê°„ 시장 ë…ì ê¶� ë“� 중요í•� 혜íƒì� 제공합니ë‹�.

KLTO-202ëŠ� 'ë°ìФë¯�(desmin)'ì´ë¼ëŠ� 근육 특ì´ì � 프로모터ë¥� 사용하여 s-KL 유전ìžì™€ ë‹¨ë°±ì§ˆì„ ë°œí˜„ì‹œì¼œ, ì‹ ê²½ê·� ì ‘í•©ë¶€ì—� 치료제를 특ì´ì ìœ¼ë¡� 전달하는 ìš´ë™ ì‹ ê²½ 질환ì� 표ì ìœ¼ë¡œ 합니ë‹�. 회사ëŠ� ë‘� 가지 ë™ë¬¼ 모ë¸ì—서 ê°œë… ì¦ëª… 연구ë¥� 완료했으ë©�, 제조ë¥� 시작하고 FDA ë°� EMA와ì� 규제 회ì˜ë¥� ê³„íš ì¤‘ìž…ë‹ˆë‹¤.

Klotho Neurosciences (NASDAQ:KLTO) a obtenu la désignation de médicament orphelin par la FDA pour KLTO-202, sa nouvelle thérapie génique promoteur du gène secreted-Klotho pour le traitement de la sclérose latérale amyotrophique (SLA). Cette désignation offre des avantages significatifs, notamment des crédits d'impôt pour les essais cliniques, des exonérations des frais GDUFA et 7 ans d'exclusivité sur le marché.

KLTO-202 cible les maladies des motoneurones en utilisant un promoteur spécifique aux muscles appelé « desmine » pour exprimer le gène et la protéine s-KL, délivrant la thérapie spécifiquement à la jonction neuromusculaire. La société a achevé des études de preuve de concept sur deux modèles animaux et lance la fabrication tout en planifiant des réunions réglementaires avec la FDA et l'EMA.

Klotho Neurosciences (NASDAQ:KLTO) hat von der FDA die Orphan-Drug-Designation für KLTO-202 erhalten, eine neuartige secreted-Klotho-Promotor-Gentherapie zur Behandlung der Amyotrophen Lateralsklerose (ALS). Diese Designation bringt bedeutende Vorteile mit sich, darunter Steuergutschriften für klinische Studien, GDUFA-Gebührenbefreiungen und 7 Jahre Marktexklusivität.

KLTO-202 zielt auf Motoneuronerkrankungen ab und verwendet einen muskel-spezifischen Promotor namens „Desmin�, um das s-KL-Gen und -Protein zu exprimieren und die Therapie gezielt an der neuromuskulären Verbindung zu verabreichen. Das Unternehmen hat Konzeptnachweise in zwei Tiermodellen abgeschlossen und beginnt mit der Herstellung, während es regulatorische Gespräche mit der FDA und EMA plant.

Positive
  • Received FDA Orphan Drug Designation providing 7 years of market exclusivity
  • Successful completion of proof of concept studies in two animal models
  • Tax credits and fee waivers granted through Orphan Drug Designation
  • Targeting a rare disease market with 5,000 new cases annually in the US
Negative
  • KLTO-202 is not yet approved for human use by any regulatory authority
  • Early stage of development with clinical trials still pending
  • Faces challenges in treating a universally fatal disease

Insights

FDA's Orphan Drug Designation for KLTO-202 provides Klotho significant regulatory advantages for their ALS treatment candidate, boosting development prospects.

The FDA's grant of Orphan Drug Designation (ODD) to Klotho Neurosciences for KLTO-202 represents a significant regulatory milestone in the company's ALS treatment development program. This designation offers substantial benefits including tax credits for clinical trial costs, GDUFA user fee waivers, and critically, seven years of market exclusivity upon approval—independent of patent protection.

KLTO-202 (s-KL-AAV.myo) utilizes a novel approach combining a secreted-Klotho promoter with gene therapy delivered to the neuromuscular junction. The therapy aims to address both the neurological damage and offer neuroprotection through therapeutic concentrations of the s-KL protein in blood, brain, and muscle tissues.

The company has completed proof-of-concept studies in two animal models and is initiating manufacturing of the candidate. Their regulatory strategy includes upcoming consultations with both FDA and EMA to establish the development pathway.

For context, ALS affects fewer than 200,000 people in the US with approximately 5,000 new diagnoses annually, qualifying it as a rare disease. The ODD validates Klotho's scientific approach while providing regulatory advantages to accelerate development for this universally fatal condition that currently has limited treatment options.

NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or s-KL-AAV.myo) for the treatment of ALS.

The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The Orphan Drug Designation provides certain incentives, such as tax credits, toward the cost of human clinical trials and a waiver for the payment of the GDUFA User Fee for market applications. Additionally, Orphan Drug Designation of the product provides the developers seven years of US market exclusivity and independent from the Company's intellectual property protection.

"Receiving the Orphan Drug Designation for s-KL-AAV.myo for the early treatment of ALS underscores the importance of bringing new treatment options to patients suffering from this rare, universally fatal disease" said Dr. Joseph Sinkule, Klotho's Chief Executive Officer. "My cousin Karen died from this horrific disease. We aim to deliver the first gene replacement therapy addressing the neurologic insult resulting in motor neuron damage and the potential neurologic protection induced by providing therapeutic blood, brain, and muscle concentrations of the s-KL protein. After the FDA's review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease" concludes Dr. Sinkule.

ALS is sometimes referred to as Lou Gehrig's disease. Lou Gehrig, who played for the New York Yankees for 17 years in the 1920s and 1930s, stunned players and fans by retiring from baseball at the age of 36 after being diagnosed with ALS. Prior to this diagnosis, Gehrig played in a record-breaking 2,130 consecutive games, was referred to as the "Iron Horse," and was considered one of the greatest baseball players of all time. Less than two years later, at the age of 37, Gehrig died of complications from ALS. ALS is also referred to as Motor Neuron Disease in the UK and elsewhere. ALS is considered a rare disease and affects fewer than 200,000 people in the US, with around 5,000 new cases diagnosed each year.

Klotho Neurosciences will have completed "proof of concept" studies in two animal models of human ALS and the Company is currently initiating manufacturing of the ALS-targeted product candidate, followed by meetings with the U.S. FDA and EMA in Europe to concur with the development path going forward.

KLTO-202, the company's lead product candidate targeting motor neuron diseases and muscular dystrophies, is composed of a muscle-specific promoter called "desmin," driving the expression of the s-KL gene transcript and s-KL protein, with targeted delivery of the gene therapy to the neuromuscular junction - the interface between the spinal cord and the muscles. At this time, KLTO-202 is not approved for human use by any regulatory authority.

About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, please visit the company's website at .

Investor Contact and Corporate Communications: - Jeffrey LeBlanc, CFO
[email protected]

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, . All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Cision View original content to download multimedia:

SOURCE Klotho Neurosciences, Inc.

FAQ

What is the significance of KLTO receiving Orphan Drug Designation for its ALS treatment?

The FDA Orphan Drug Designation grants KLTO tax credits for clinical trials, fee waivers, and 7 years of market exclusivity for KLTO-202, their ALS treatment candidate.

How does Klotho Neurosciences' KLTO-202 work in treating ALS?

KLTO-202 uses a muscle-specific promoter called desmin to express the s-KL gene and protein, delivering therapy to the neuromuscular junction between the spinal cord and muscles.

What is the current development stage of KLTO-202 for ALS treatment?

KLTO-202 has completed proof of concept studies in two animal models and is initiating manufacturing, with planned regulatory meetings with the FDA and EMA.

How many people are affected by ALS in the United States?

ALS affects fewer than 200,000 people in the US, with approximately 5,000 new cases diagnosed each year.

What regulatory approvals has KLTO-202 received so far?

KLTO-202 has received FDA Orphan Drug Designation but is not yet approved for human use by any regulatory authority.
Klotho Neurosciences, Inc.

NASDAQ:KLTO

KLTO Rankings

KLTO Latest News

KLTO Stock Data

38.68M
36.76M
60.28%
9.71%
0.99%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
NEW YORK